RayKnowChina Research Map
Shortlist

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病NMOSD

A group of inflammatory conditions that mainly affect the optic nerves and the spinal cord. Most people with it have antibodies to the protein aquaporin-4; some do not.

Definition adapted from MeSH (US National Library of Medicine), Wingerchuk 2015

Listed in China's first national rare-disease catalogue (2018, no. 81). National Health Commission 国卫医发〔2018〕10号

hospitals in mainland China
67

with a paper from 2016–2025 or a registered study

cities
29

where those hospitals are

open trials in China
32

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 27% of the world's English-language research papers on neuromyelitis optica spectrum disorder, 2021–2025 (21% in 2016–2020), and 41% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

67 hospitals in 29 cities

Order: papers led on neuromyelitis optica spectrum disorder, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 2 papers or 1 trial on neuromyelitis optica spectrum disorder, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing12
  2. Guangzhou9
  3. Shanghai4
  4. Hangzhou3
  5. Jinan3
  6. Xiamen3
  7. Changchun2
  8. Changsha2
  9. Chengdu2
  10. Hefei2

Each opens neuromyelitis optica spectrum disorder in that city. 19 more cities are in the menu below.

  1. 39 papers led
  2. 36 papers led
    No open trial led
  3. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    34 papers led
  4. 23 papers led
  5. 22 papers led
  6. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    18 papers led
  7. 16 papers led
    No open trial led
  8. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    12 papers led
  9. 11 papers led
    No open trial led
  10. 11 papers led
    No open trial led
  11. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    11 papers led
  12. 10 papers led
    No open trial led
  13. 8 papers led
    No open trial led
  14. 8 papers led
    No open trial led
  15. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    7 papers led
    No open trial led
  16. 7 papers led
    No open trial led
  17. 7 papers led
    No open trial led
  18. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    7 papers led
    No open trial led
  19. 7 papers led
    No open trial led
  20. 6 papers led
    No open trial led
  21. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    6 papers led
    No open trial led
  22. 5 papers led
    No open trial led
  23. 5 papers led
    No open trial led
  24. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    5 papers led
    No open trial led
  25. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    5 papers led
  26. Xiangya Hospital

    中南大学湘雅医院Changsha

    5 papers led
    No open trial led
  27. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    5 papers led
  28. 4 papers led
    No open trial led
  29. 4 papers led
    No open trial led
  30. 4 papers led
    No open trial led
  31. Zhongshan Ophthalmic Center

    中山大学中山眼科中心Guangzhou

    4 papers led
    No open trial led
  32. 3 papers led
    No open trial led
  33. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    3 papers led
    No open trial led
  34. 3 papers led
    No open trial led
  35. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    3 papers led
    No open trial led
  36. 3 papers led
    No open trial led
  37. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    3 papers led
    No open trial led
  38. 2 papers led
    No open trial led
  39. 2 papers led
    No open trial led
  40. 2 papers led
    No open trial led
  41. 2 papers led
    No open trial led
  42. 2 papers led
    No open trial led
  43. 2 papers led
    No open trial led
  44. 2 papers led
    No open trial led
  45. 2 papers led
    No open trial led
  46. 2 papers led
    No open trial led
  47. 2 papers led
    No open trial led
  48. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    2 papers led
    No open trial led
  49. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    2 papers led
    No open trial led
  50. Western Medicine Integrated Hospital

    杭州市红十字会医院(浙江省中西医结合医院)Hangzhou

    2 papers led
    No open trial led
  51. Yuquan Hospital

    清华大学玉泉医院Beijing

    2 papers led
    No open trial led
  52. 1 paper led
  53. 1 paper led
    No open trial led
  54. 1 paper led
    No open trial led
  55. 1 paper led
    No open trial led
  56. 1 paper led
    No open trial led
  57. Tianjin Huanhu Hospital

    天津市环湖医院Tianjin

    1 paper led
  58. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    1 paper led
    No open trial led
  59. 0 papers led
    No open trial led
  60. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    0 papers led
    No open trial led
  61. 0 papers led
    No open trial led
  62. 0 papers led
    No open trial led
  63. 0 papers led
  64. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    0 papers led
  65. Xiamen Hospital

    厦门市中医院Xiamen

    0 papers led
  66. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    0 papers led
    No open trial led
  67. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    0 papers led
    No open trial led

By university or health system 36

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Capital Medical University

    首都医科大学Beijing

    51 papers led
    6 hospitals
  2. Sun Yat-sen University

    中山大学Guangzhou

    46 papers led
    3 hospitals
  3. Sichuan University (West China)

    四川大学华西Chengdu

    36 papers led
    1 hospital
  4. Fudan University

    复旦大学Shanghai

    23 papers led
    2 hospitals
  5. Tianjin Medical University

    天津医科大学Tianjin

    22 papers led
    1 hospital
  6. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    19 papers led
    2 hospitals
  7. Hebei Medical University

    河北医科大学Shijiazhuang

    17 papers led
    2 hospitals
  8. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    15 papers led
    3 hospitals
  9. Jilin University

    吉林大学Changchun

    14 papers led
    2 hospitals
  10. Zhengzhou University

    郑州大学Zhengzhou

    14 papers led
    3 hospitals
  11. Central South University (Xiangya)

    中南大学湘雅Changsha

    12 papers led
    2 hospitals
  12. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    12 papers led
    1 hospital
  13. Soochow University

    苏州大学Suzhou

    12 papers led
    2 hospitals
  14. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    10 papers led
    2 hospitals
  15. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    10 papers led
    2 hospitals
  16. Chongqing Medical University

    重庆医科大学Chongqing

    9 papers led
    2 hospitals
  17. Shandong University

    山东大学Jinan

    9 papers led
    2 hospitals
  18. China Medical University (Shenyang)

    中国医科大学Shenyang

    8 papers led
    2 hospitals
  19. 8 papers led
    2 hospitals
  20. Wenzhou Medical University

    温州医科大学Wenzhou

    8 papers led
    4 hospitals
  21. Air Force Medical University

    空军军医大学Xi'an

    6 papers led
    1 hospital
  22. Fujian Medical University

    福建医科大学Fuzhou

    6 papers led
    2 hospitals
  23. Nanchang University

    南昌大学Nanchang

    5 papers led
    2 hospitals
  24. Southern Medical University

    南方医科大学Guangzhou

    5 papers led
    3 hospitals
  25. Nanjing Medical University

    南京医科大学Nanjing

    4 papers led
    2 hospitals
  26. Anhui Medical University

    安徽医科大学Hefei

    3 papers led
    2 hospitals
  27. Guangxi Medical University

    广西医科大学Nanning

    3 papers led
    1 hospital
  28. Guangzhou Medical University

    广州医科大学Guangzhou

    3 papers led
    4 hospitals
  29. Peking University Health Science Center

    北京大学医学部Beijing

    3 papers led
    2 hospitals
  30. Shandong First Medical University

    山东第一医科大学Jinan

    3 papers led
    2 hospitals
  31. Harbin Medical University

    哈尔滨医科大学Harbin

    2 papers led
    2 hospitals
  32. 2 papers led
    1 hospital
  33. Kunming Medical University

    昆明医科大学Kunming

    1 paper led
    1 hospital
  34. Nanjing University

    南京大学Nanjing

    1 paper led
    1 hospital
  35. Qingdao University

    青岛大学Qingdao

    1 paper led
    1 hospital
  36. 1 paper led
    0 hospitals

32

open trials on neuromyelitis optica spectrum disorder in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 28 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT05199688

    Age 2 years to 11 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  2. Recruiting
    Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
    Phase
    Phase 4
    Started
    2026-02
    Registry
    NCT07410039

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07420296

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  4. Recruiting
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07526493

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07762872

    Age 18 years to Not stated (registered criteria)

    Led by Xuanwu HospitalBeijing

  6. Recruiting
    The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06620809

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  7. Recruiting
    Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06763848

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  8. Recruiting
    HANDLE-a Real World Study on Satralizumab in NMOSD
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06829524

    Age 12 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  9. Recruiting
    Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT06885957

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  10. Recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06939166

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  11. Recruiting
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT07022197

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  12. Recruiting
    Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07377305

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  13. Recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06249438

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  14. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  15. Recruiting
    Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06474520

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  16. Recruiting
    Biomarkers in Autoimmune Disease of Nervous System
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06502015

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  17. Recruiting
    Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06541626

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  18. Recruiting
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT07653984

    Age 20 years to 55 years; women only (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  19. Recruiting
    A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06697535

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  20. Recruiting
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    Phase
    Early phase 1
    Started
    2022-04
    Registry
    NCT05145361

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an

  21. Recruiting
    Ofatumumab in AQP4-IgG Seropositive NMOSD
    Phase
    Phase 1/Phase 2
    Started
    2022-06
    Registry
    NCT05504694

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  22. Recruiting
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    Phase
    Early phase 1
    Started
    2020-09
    Registry
    NCT04561557

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  23. Recruiting
    Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
    Phase
    Not given
    Started
    2019-01
    Registry
    NCT04106830

    Age 16 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  24. Not yet recruiting
    Tongji NADs Cohort
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07333196

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  25. Not yet recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07392528

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  26. Not yet recruiting
    The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07592754

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  27. Not yet recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07676266

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  28. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

  29. Not yet recruiting
    Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07809724

    Age 18 years to 74 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  30. Not yet recruiting
    Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
    Phase
    Early phase 1
    Started
    2025-02
    Registry
    NCT06485232

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  31. Not yet recruiting
    Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07266051

    Age 18 years to Not stated (registered criteria)

    Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen

  32. Enrolling by invitation
    Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06643858

    Age 6 years to 90 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions